Three RDT platforms (Verigene BC-GN, BioFire® BCID, and BCID 2 (RUO)) were compared using the Desirability of Outcome Ranking Management of Antimicrobial Therapy (DOOR -MAT) to evaluate potential downstream antimicrobial prescribing decisions resulting from the panels different organism and resistance detection. BioFire BCID (RUO) had the best mean DOOR-MAT scores.
Reference Type
Journal Article
Periodical Full
Clinical infectious diseases
Publication Year
2021
Publication Date
Mar 27,
Place of Publication
United States
ISSN/ISBN
1058-4838
Document Object Index
10.1093/cid/ciab262
URL
https://www.ncbi.nlm.nih.gov/pubmed/33772269
PMID
33772269